BDSX
Biodesix, Inc.NASDAQHealthcare$15.36+1.92%ClosedMarket Cap: $116.0M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
-50.25
P/S
1.31
EV/EBITDA
-7.73
DCF Value
$-271.53
FCF Yield
-20.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.1%
Operating Margin
-31.5%
Net Margin
-39.8%
ROE
-1760.8%
ROA
-40.3%
ROIC
-39.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $28.8M | 83.0% | $-2.0M | $-4.0M | $-0.49 | — |
| FY 2025 | $88.5M | 75.2% | $-27.9M | $-35.3M | $-4.67 | — |
| Q3 2025 | $21.8M | 81.1% | $-7.1M | $-8.7M | $-1.16 | — |
| Q2 2025 | $20.0M | 79.9% | $-9.7M | $-11.5M | $-1.60 | — |
| Q1 2025 | $18.0M | 79.4% | $-9.1M | $-11.1M | $-1.60 | — |
| Q4 2024 | $20.4M | 78.7% | $-6.6M | $-8.3M | $-1.20 | — |
| FY 2024 | $71.3M | 78.2% | $-34.5M | $-42.9M | $-6.60 | — |
| Q3 2024 | $18.2M | 77.0% | $-8.6M | $-10.3M | $-1.40 | — |
| Q2 2024 | $17.9M | 78.4% | $-8.2M | $-10.8M | $-1.60 | — |
| Q1 2024 | $14.8M | 78.6% | $-11.0M | $-13.6M | $-0.14 | — |
| Q4 2023 | $14.7M | 77.0% | $-6.8M | $-9.1M | $-1.98 | — |
| FY 2023 | $49.1M | 73.5% | $-41.3M | $-52.1M | $-12.80 | — |